Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41198   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-003371-13
    Sponsor's Protocol Code Number:IM101084
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2007-01-22
    Trial results Removed from public view
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2006-003371-13
    A.3Full title of the trial
    A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy.

    Revised Protocol 02 incorporating Amendments 02 (Version 1.0, Date: 06-Dec-2006) and 03 (Version 1.0, Date: 05-Mar-2007).
    + Protocol Amendment 06 - Site specific - U.K. (Version 1.0, Date: 26-Jun-2007).
    + Pharmacogenetics Blood Sample Protocol Amendment 01 - Site Specific (version 2.0, Date 26-Oct-2006).
    A.4.1Sponsor's protocol code numberIM101084
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBristol-Myers Squibb International Corporation
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAbatacept
    D.3.2Product code BMS-188667
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAbatacept
    D.3.9.1CAS number 332348-12-6
    D.3.9.2Current sponsor codeBMS-188667
    D.3.9.3Other descriptive nameCTLA4Ig
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeFusion Protein
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Crohn's disease, NOS
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 8.1
    E.1.2Level LLT
    E.1.2Classification code 10011401
    E.1.2Term Crohn's disease
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    * Placebo-Controlled Induction Period:
    Compare the proportion of subjects who have a clinical response (as defined by a reduction in Crohn’s Disease Activity Index [CDAI] >= 100 or an absolute CDAI score < 150) at both Day IP-57 (Week 8) and Day IP-85 (Week 12) between the abatacept and placebo treatment regimens.

    * Maintenance Period:
    Compare the proportion of subjects who are in clinical remission
    (CDAI < 150) at Day MP-365 (12 months) between the abatacept and placebo treatment regimens.

    * Open-label Extension Phase:
    Assess the long-term clinical safety and tolerability of abatacept treatment.
    E.2.2Secondary objectives of the trial
    Induction Period (IP):
    -Compare proportion of subjects in clinical remission at both Day IP-57 & IP-85 between abatacept & placebo treatment regimens
    -Evaluate dose-response relationship by comparing proportions of subjects with a clinical response at both Day IP-57 & IP-85 induced by placebo & abatacept in increasing doses
    -Assess improvements in quality of life at Day IP-85 using the IBD Questionnaire in abatacept vs. placebo treated subjects

    Maintenance Period (MP):
    -Compare proportion of subjects between abatacept & placebo treatment regimens:
    • who have a clinical response at Day MP-365
    • in clinical remission at both Day MP-169 & MP-365
    -Assess in abatacept vs. placebo treated subjects improvements in quality of life using the SF-36 & IBD Questionnaire

    *IP+MP:
    Assess tolerability & safety of abatacept in subjects with CD
    Assess immunogenicity of abatacept in subjects with CD


    See Protocol Sections 2.1.2, 2.2.2, 2.3.2 for additional secondary objectives
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Signed written informed consent
    2) Subject must have had CD for at least 3 months from the time of initial diagnosis.
    Active CD must be confirmed by radiologic, endoscopic or histologic evidence within
    the previous 12 months. If previous confirmation of diagnosis is not available or if
    previous diagnosis is not deemed conclusive at time of screening, CD diagnosis
    should be confirmed by endoscopy, radiology or histology.
    3) Subjects must satisfy at least one of the following criteria:
    a/ In the past had an inadequate response to at least 1 of the following treatments:
    i) oral prednisone >= 40 mg/day (or equivalent) or budesonide >= 9 mg/day for at
    least 2 weeks and/or
    ii) immunosuppressants (azathioprine >= 2 mg/kg/day or 6-mercaptopurine >=
    1.0 mg/kg/day [or documentation of a therapeutic concentration of
    6-thioguanine nucleotide] or methotrexate >= 15 mg/week) for at least 12
    weeks and/or
    iii) an approved anti-TNF agent at an approved labeled dose for at least 8 weeks
    AND/OR
    b/ Have been intolerant to one of the above mentioned treatments (e.g., unable to
    achieve doses or treatment durations because of dose limiting side effects [e.g.,
    leukopenia, psychosis, uncontrolled diabetes, elevated liver enzymes]).
    AND/OR
    c/ Currently receiving one or more of the following treatments:
    i) oral prednisone >= 20 mg/day (or equivalent) or budesonide >= 3 mg/day for at
    least 4 weeks and/or
    ii) immunosuppressants [azathioprine >= 2 mg/kg/day or 6-mercaptopurine >=
    1.0 mg/kg/day, (or documentation of a therapeutic concentration of 6-thioguanine
    nucleotide)] for at least 12 weeks.
    Subjects currently receiving and tolerating the above mentioned treatments (with
    the exception of anti-TNF agents) should continue their treatment (see Drug Stabilization Requirements, Protocol Section 6.4.2.1). Subjects who had an inadequate response and/or intolerance to anti-TNF treatment must have had their last dose at least 8 weeks prior to entry into the Induction Period.
    Acceptable documentation of inadequate response or intolerance in subjects include 1 or more of the following: medical records; letters provided by the referring physician; other referral documents (e.g., insurance authorization forms), provided they contain the relevant information to support the subject’s ‘inadequate response’ and/or ‘intolerance’ to the designated therapy.
    In all circumstances, it should be established that discontinuation of the designated
    treatments was primarily due to lack of efficacy or intolerance (e.g., not due to
    unavailability of the drug).
    Subjects in clinical remission should not discontinue CD therapy that is maintaining
    clinical remission, for the purpose of meeting eligibility requirements to enroll into this
    study.
    4) Moderate to severe CD as measured by a CDAI score >= 220 and =< 450
    5) hsCRP > Upper Limit of Normal (ULN)
    6) Oral corticosteroid treatment must have been reduced to the equivalent of =< 30 mg prednisone or =< 9 mg budesonide daily at a stable dose for at least 2 weeks prior to entry into the Induction Period
    7) Oral aminosalicylates should be at a stable dose for at least 2 weeks prior to entry into the Induction Period
    8) Azathioprine, 6-mercaptopurine and methotrexate should be at a stable dose for at least 8 weeks prior to entry into the Induction Period
    9) Men and women, ages >= 18
    E.4Principal exclusion criteria
    1)WOCBP unwilling or unable to use an acceptable method to avoid pregnancy for entire study period & for up to 10 weeks after study
    2)WOCBP using a prohibited contraceptive method
    3)pregnant or breastfeeding women
    4)Women with positive pregnancy test on enrollment or prior to study drug administration
    5)Diagnosis of Ulcerative or Indeterminate Colitis
    6)CD isolated to stomach, duodenum, jejunum, or perianal region without colonic or ileal involvement
    7)Suspected or diagnosed intra-abdominal or perianal abscess at screening
    8)Known strictures or stenosis (without inflammatory component) leading to symptoms or obstruction
    9)Current evidence of fulminant colitis, toxic megacolon or bowel perforation
    10)Current stoma or current need for colostomy or ileostomy. Use of seton for perianal disease
    11)Previous total proctocolectomy or subtotal colectomy with ileorectal anastomosis
    12)Surgical bowel resection <6 months before screening
    13)Extensive small bowel resection or known short bowel syndrome
    14)Primary sclerosing cholangitis
    15)Currently receiving total parenteral nutrition
    16)Past/current evidence of definite low grade or high grade colonic dysplasia
    17)Subjects who are scheduled or anticipate the need for surgery aside from
    dermatologic procedures
    18)History of clinically significant drug or alcohol abuse
    19)Concomitant illness, likely to require systemic glucocorticosteroid therapy during study (e.g. moderate to severe asthma)
    20)Current symptoms of severe, progressive, or uncontrolled renal, hepatic,
    hematological, pulmonary, cardiac, neurological, ophthalmologic or cerebral disease
    Concomitant medical conditions that might place subject at unacceptable risk for participation in study
    21)Subjects with a history or current evidence of malignancies; specifically subjects with
    a)history of cancer within last 5 years (other than NMSC cancers cured by local resection) or
    b)evidence of malignancies (including that detected by screening procedures), or
    c)signs of possible malignancies detected by screening procedures for which the
    workup to exclude malignancy has not been completed.
    The following subjects may be enrolled; those with
    a)existing NMSC cancers which have been entirely removed prior to enrollment, or
    b)carcinoma in situ treated with definitive surgical intervention
    c)no evidence of malignancy upon completion of evaluation prompted by suspicious screening procedure.
    22)Subjects at risk for tuberculosis
    23)Subjects with any serious bacterial infection within last 3 months, unless treated & resolved with antibiotics, or any chronic bacterial infection
    24)Female subjects who have had breast cancer screening that is suspicious for
    malignancy, & in whom the possibility of malignancy cannot be reasonably
    excluded following additional clinical, laboratory or other diagnostic evaluations (Protocol Section 7.3.2.4)
    25)Subjects with evidence of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of HIV, Hepatitis B or Hepatitis C infection detected during screening
    26)Subjects with herpes zoster or cytomegalovirus that resolved <2 months before signing ICF
    27)Subject who have received any live vaccines within 3 months of the anticipated first dose of study medication or who will have need of a live vaccine at any time following entry in Induction Period (IP)
    28)Subject with a clinically significant abnormal chest x-ray at screening
    29)Positive stool culture for enteric pathogens
    30)Stool positive for C. Difficile toxin
    31)Any of the following lab values
    • Hgb <8.5 g/dL
    • WBC <3,000/mm³ (3x 109/L)
    • Platelets <100,000/mm³ (100 x 109/L)
    • Serum creatinine> 2x upper limit of normal
    • Serum ALT or AST> 3x upper limit of normal
    • Any other laboratory test results that, in the opinion of the Investigator, might
    place the subject at unacceptable risk for participation in this study
    32)History of severe or anaphylactic infusion reaction after receiving a biologic agent, suspected to be associated with an immune response
    33)CTLA4Ig or abatacept at any point in time before screening
    34)Any marketed biologic used for CD (including infliximab) within 8 weeks before
    entry in IP
    35)Any biologic immunomodulators used for CD or other conditions within 8 weeks
    before entry in IP
    36)Rituximab within 1 year before screening
    37)Parenteral corticosteroids within 4 weeks or rectal administration of corticosteroids within 2 weeks before entry in IP
    38)Rectal administration of 5-ASA within 2 weeks before entry in IP
    39)Tacrolimus, cyclosporine, mycophenolate mofetil (CellCept®), immunoadsorption
    columns (such as Prosorba columns), D Penicillamine, Leflunomide, Thalidomide, probiotics, non-steroidal anti-inflammatory agents, aspirin >81mg/day within 2 weeks before entry in IP

    See Protocol Section 5.2 for additional Exclusion Criteria
    E.5 End points
    E.5.1Primary end point(s)
    * The Induction Period’s primary efficacy assessment will test for differences in the proportion of subjects in the Induction Period abatacept 30/~10mg/kg treatment regimen versus placebo and abatacept ~10mg/kg treatment regimen versus placebo who are in clinical response on Days IP-71 and IP-85. The Induction Period’s two primary comparisons will be tested using the Cochran-Mantel-Haenszel (CMH) Chi-square test at the 5% level of significance with stratification according to the Induction Period stratification factors:
    1) disease severity, and
    2) concomitant use of immunosuppressants.


    * The primary efficacy assessment of the Maintenance Period will test for treatment differences in the proportion of subjects who are in clinical remission at Day MP-365. The CMH Chi-square test will be used to compare the two treatment groups at the 5% level of significance, with stratification according to the Maintenance Period stratification factors:
    1) disease activity following Induction therapy, and
    2) concomitant use of immunosuppressants.


    * Safety Analysis:
    Significant physical examination findings, and clinical and laboratory test results will be listed. Summary statistics will be tabulated. Frequency distributions and individual
    listings of all adverse events will be generated. Changes from baseline in clinical
    laboratory test results will be listed.

    * PK Analysis:
    Summary statistics will be tabulated for PK parameters by dose groups. Geometric means and coefficients of variation will be presented for Cmax, Cmin and AUC (TAU).
    Medians and ranges (minimum and maximum) will be presented for Tmax.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity + health related Quality of Life: IBD Questionnaire and SF-36 questinonaire
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA54
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Information not present in EudraCT
    F.1.3Elderly (>=65 years) Information not present in EudraCT
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 228
    F.4.2.2In the whole clinical trial 906
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The Open-label Extension (OL) phase will be offered to subjects who complete the 12- week Induction Period and do not meet responder criteria at Day IP-85, subjects who experience disease relapse during the Maintenance Period, and subjects who complete the Maintenance Period. To allow for the continued collection of safety data in an open-label long-term extension phase, the Open-label Extension will continue until the drug is marketed for CD or the CD development program is discontinued.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-02-14
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-08-16
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA